Association between Thromboembolic Events and the <I>JAK2</I> V617F Mutation in Myeloproliferative Neoplasms-Reference-Cited by-同舟云学术

Association between Thromboembolic Events and the JAK2 V617F Mutation in Myeloproliferative Neoplasms

Published:2014 Issue:3.4 Volume:60 Page:89-97
ISSN:0023-5679
Container-title:The Kurume Medical Journal
language:en
Short-container-title:Kurume Med. J.

Author:

TAKATA YUKA¹,SEKI RITSUKO¹,KANAJII TAISUKE¹,NOHARA MASAYUKI¹,KOTEDA SATOKO¹,KAWAGUCHI KUNIKI¹,NOMURA KEI¹,NAKAMURA TAKAYUKI¹,MORISHIGE SATOSHI¹,OKU EIJIROU¹,OSAKI KOICHI¹,HASHIGUCHI EMICHITOSHI¹,MOURI FUMIHIKO¹,YOSHIMOTO KOJI¹,NAGAFUJI KOJI¹,OKAMURA TAKASHI¹

Affiliation:

1. Department of Medicine, Kurume University School of Medicine

Publisher

Kurume Medical Journal

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/kurumemedj/60/3.4/60_MS63001/_pdf

Reference36 articles.

1. 1. Kralovics R, Passamonti F, Buser AS, Teo SS, Skoda RC et al. A Gain-of-Function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90.

2. 2. Baxter E, Scott LM, Campbell P, East C, Fourouclas N et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.

3. 3. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends in Molecular Medicine 2005; 11:1471-4914.